Associations Between COVID-19 Vaccination Status and Persistent Symptoms: A Prospective Study of Reproductive-Age Women

IF 2.1 4区医学 Q3 HEALTH CARE SCIENCES & SERVICES

Journal of evaluation in clinical practice Pub Date : 2025-02-07 DOI:10.1111/jep.70005

Ilkin Seda Can Caglayan, Gulbahtiyar Demirel, Ceren Eda Can

{"title":"Associations Between COVID-19 Vaccination Status and Persistent Symptoms: A Prospective Study of Reproductive-Age Women","authors":"Ilkin Seda Can Caglayan, Gulbahtiyar Demirel, Ceren Eda Can","doi":"10.1111/jep.70005","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>The present study was conducted to determine the relationship between prolonged complaints of women who had COVID-19 infection and whose symptoms persisted and their vaccination status against COVID-19.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This prospective observational study consisted of three groups [The Unvaccinated Group (Control Group: 89), the BioNTech Vaccine Group (114 people), and the Sinovac Vaccine Group (84 people)]. In this study, which included 287 women, prolonged COVID-19 symptoms in their spouses were also questioned. Information was obtained from the participants in the form of questions and answers under outpatient clinical conditions 2 months after their recovery. Women between the ages of 18–45 who had regular menstrual periods in the last 6 months before the pandemic, those whose COVID-19 test was negative and those who received a single dose of vaccine in the vaccinated group were included in the study.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The rates of loss of taste and prolonged symptoms of high fever in Sinovac-vaccinated participants were lower than in the other groups in the present study (<i>p</i> < 0.05). A total of 40.5% of those who were vaccinated with Sinovac after COVID-19 had a menstrual cycle length of every 28–40 days, which was higher than the percentage of participants in other groups, and 40.5% of those in this group did not have menstrual pain. Additionally, the menstrual period length of 62.3% of the participants who received the BioNTech vaccine increased (<i>p</i> < 0.05). This increase is higher than the participants in the other group.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>The study indicated that certain prolonged symptoms of COVID-19 infection were less common among participants vaccinated with Sinovac. In this group, the menstrual cycle length increased, while menstrual pain decreased.</p>\n </section>\n </div>","PeriodicalId":15997,"journal":{"name":"Journal of evaluation in clinical practice","volume":"31 1","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of evaluation in clinical practice","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jep.70005","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

The present study was conducted to determine the relationship between prolonged complaints of women who had COVID-19 infection and whose symptoms persisted and their vaccination status against COVID-19.

Methods

This prospective observational study consisted of three groups [The Unvaccinated Group (Control Group: 89), the BioNTech Vaccine Group (114 people), and the Sinovac Vaccine Group (84 people)]. In this study, which included 287 women, prolonged COVID-19 symptoms in their spouses were also questioned. Information was obtained from the participants in the form of questions and answers under outpatient clinical conditions 2 months after their recovery. Women between the ages of 18–45 who had regular menstrual periods in the last 6 months before the pandemic, those whose COVID-19 test was negative and those who received a single dose of vaccine in the vaccinated group were included in the study.

Results

The rates of loss of taste and prolonged symptoms of high fever in Sinovac-vaccinated participants were lower than in the other groups in the present study (p < 0.05). A total of 40.5% of those who were vaccinated with Sinovac after COVID-19 had a menstrual cycle length of every 28–40 days, which was higher than the percentage of participants in other groups, and 40.5% of those in this group did not have menstrual pain. Additionally, the menstrual period length of 62.3% of the participants who received the BioNTech vaccine increased (p < 0.05). This increase is higher than the participants in the other group.

Conclusion

The study indicated that certain prolonged symptoms of COVID-19 infection were less common among participants vaccinated with Sinovac. In this group, the menstrual cycle length increased, while menstrual pain decreased.

查看原文本刊更多论文

COVID-19疫苗接种状况与持续症状之间的关系：育龄妇女的前瞻性研究

目的探讨COVID-19感染妇女持续症状的持续主诉与接种COVID-19疫苗情况的关系。方法本前瞻性观察性研究分为三组[未接种组（对照组：89人），BioNTech疫苗组（114人）和Sinovac疫苗组（84人）]。在这项包括287名女性的研究中，她们的配偶长期出现COVID-19症状也受到了质疑。在康复2个月后，以门诊临床条件下的问答形式从参与者获得信息。年龄在18-45岁之间、在大流行前6个月月经规律的女性、COVID-19检测呈阴性的女性以及接种疫苗组中接种单剂疫苗的女性都被纳入了这项研究。结果在本研究中，接种中国疫苗组的味觉丧失率和高热症状延长率低于其他组（p < 0.05）。在新冠肺炎后接种科兴疫苗的参与者中，40.5%的人的月经周期长度为每28-40天，高于其他组的参与者比例，并且该组中40.5%的人没有月经疼痛。此外，62.3%接受BioNTech疫苗的参与者月经周期延长（p < 0.05）。这一增幅高于另一组的参与者。结论本研究表明，在接种科兴疫苗的参与者中，某些延长的COVID-19感染症状较少。在该组中，月经周期长度增加，而月经疼痛减轻。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of evaluation in clinical practice 医学-卫生保健

CiteScore

4.80

自引率

4.20%

发文量

143

审稿时长

3-8 weeks

期刊介绍： The Journal of Evaluation in Clinical Practice aims to promote the evaluation and development of clinical practice across medicine, nursing and the allied health professions. All aspects of health services research and public health policy analysis and debate are of interest to the Journal whether studied from a population-based or individual patient-centred perspective. Of particular interest to the Journal are submissions on all aspects of clinical effectiveness and efficiency including evidence-based medicine, clinical practice guidelines, clinical decision making, clinical services organisation, implementation and delivery, health economic evaluation, health process and outcome measurement and new or improved methods (conceptual and statistical) for systematic inquiry into clinical practice. Papers may take a classical quantitative or qualitative approach to investigation (or may utilise both techniques) or may take the form of learned essays, structured/systematic reviews and critiques.